We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Oncologix Tech Inc (CE) | USOTC:OCLG | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0001 | 0.00 | 00:00:00 |
ALEXANDRIA, LA--(Marketwired - Jan 8, 2014) - Oncologix Tech Inc. (OTCQB: OCLG), announced today that it has closed on a $4,000,000 revolving line of credit. Under the terms of the agreement, TCA Global Credit Master Fund, L.P. committed to lend $4,000,000 through one of the Fund's Senior Secured Revolving Notes, with an initial draw of $500,000. The Company must meet specific monthly reporting and collateral requirements to further draw on the revolving credit facility.
Wayne Erwin, CEO of Oncologix, stated, "We are delighted to secure a credit facility with TCA Global that will support our company's financing needs throughout 2014. This facility will assist us with vital working capital and provide the capital structure needed to further our corporate strategy of continued growth primarily by acquisitions in our Healthcare Services division."
TCA Global is a short duration, absolute return fund specializing in senior secured lending to small, mainly listed companies in the U.S., Canada, Western Europe and Australia. The firm has a level of domestic and cross-border expertise, long-standing experience and funding innovations, as is reflected in the number of transactions completed. For more information see www.tcaglobalfund.com.
Oncologix operates and manufactures Class II medical device products and delivers Personal Healthcare Services nationally. For its clients, Oncologix provides FDA approved medical devices and State licensed healthcare services. For its shareholders, Oncologix operates profitable business divisions that build, maintain and nourish shareholder value. The Company's corporate mission is to be the best small cap medical device and healthcare services holding company in North America.
This press release may contain forward-looking statements, made in reliance upon Section 21D of the Exchange Act of 1934, which involve known and unknown risks, uncertainties or other factors that could cause actual results to differ materially from the results, performance, or expectations implied by these forward-looking statements. The Company's expectations, among other things, are dependent upon economic conditions, continued demand for its products, the availability of raw materials, retention of its key management and operating personnel, its ability to operate its subsidiary companies effectively, need for and availability of more capital as well as other uncontrollable or unknown factors which are more fully disclosed in the Company's filings with the Securities and Exchange Commission.
CONTACT INFORMATION Wayne Erwin Chairman and CEO Email Contact (318) 769-1958 INVESTOR RELATIONS Jack Eversull President The Eversull Group, Inc. 972-571-1624 214-469-2361 fax Email Contact
1 Year Oncologix Tech (CE) Chart |
1 Month Oncologix Tech (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions